

GUIDELINES WHICH PHYSICIANS MAY WANT TO INCLUDE IN LETTER
TO THE FDA

Mysteclin-F has had a definite useful place among the antibiotics prescribed in my practice, particularly for those types of patients prone to candidal infections (women with a history of candidiasis, elderly patients, debilitated patients, diabetics, patients on corticosteroids, etc.)

The NAS/NRC panel's report on Mysteclin-F indicates that they are not aware of evidence of proved efficacy in the prevention of disease due to monilial organisms, although suppression of growth of monilia may be accomplished. However, my informed medical judgment as supported by widespread medical opinion is that spread of intestinal candida to cause candidiasis is a risk which in the indicated conditions should be considered in using antibiotic therapy. The combination contained in Mysteclin-F in my experience is convenient, useful, effective, and of definite value in the care of my patients.

(Number of years physician has used Mysteclin-F since 1960.)

The FDA order to withdraw Mysteclin-F from availability for prescription use would create an unnecessary and inconvenient restriction on my prescribing freedom to the detriment of my patients.